EP3504232A1 - Kombination mit albumin, insbesondere zum behandeln eines knorpeldefekts - Google Patents
Kombination mit albumin, insbesondere zum behandeln eines knorpeldefektsInfo
- Publication number
- EP3504232A1 EP3504232A1 EP17764530.6A EP17764530A EP3504232A1 EP 3504232 A1 EP3504232 A1 EP 3504232A1 EP 17764530 A EP17764530 A EP 17764530A EP 3504232 A1 EP3504232 A1 EP 3504232A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- albumin
- groups
- functionalized
- crosslinking
- polymer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/39—Pancreas; Islets of Langerhans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/20—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
- A61L27/3826—Muscle cells, e.g. smooth muscle cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
- A61L27/3834—Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/52—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/06—Flowable or injectable implant compositions
Definitions
- the present invention relates to a combination, a reaction product, preferably in the form of a hydrogel, a medical device, a drug for advanced therapies, a kit, a Austragsvornchtung, a method for producing the combination, a process for the preparation of the reaction product, the use of a polymer for Crosslinking of albumin and a functionalized by albumin-crosslinking groups hyaluronic acid.
- dithio-PEG has the fundamental disadvantage that its production is complicated and expensive. In addition, it must be ensured that PEG is functionalized at both ends of the chain with thiol groups, since monofunctionalized PEG has an inhibitory effect on crosslinking of albumin.
- the present invention is therefore based on the object to provide an alternative combination product or combination preparation, which avoids the deficiencies known from the prior art and in particular is easier to manufacture and more biocompatible than conventional combination preparations.
- the present invention has the object to provide a functionalized hyaluronic acid, which may be in particular part of the combination preparation mentioned in the previous paragraph.
- the invention relates to a combination which has a first component and a second component spatially separated from one another.
- the first component contains crosslinkable albumin.
- the second component contains a polymer, wherein non-terminal monomer units of the polymer at least partially, in particular only partially, have an albumin-crosslinking group.
- the combination may also be referred to as combination preparation or combination product.
- the inventors have recognized that by functionalizing non-terminal monomer units ("internal functionalization") with albumin-crosslinking groups, it is possible to prepare a polymeric crosslinker for albumin whose charge with the albumin-crosslinking groups can be better controlled than for example in the case of Since a large number of non-terminal monomer units are generally available for functionalization, the risk of the formation of monofunctionalized polymers, which may optionally have an inhibiting effect on the crosslinking of albumin, is no longer possible given.
- the preparation of the polymeric crosslinker simplifies, as a stringent functionalization of all terminal monomer units, as in the known from the prior art dithio-PEG, is unnecessary. This leads to lower production times and costs.
- the combination is particularly suitable for treating, preferably reconstructing, a cartilage defect, in particular a joint cartilage defect or intervertebral disc defect.
- crosslinkable albumin should be understood as meaning an albumin which, owing to its chemical nature, in particular due to functionalization and / or derivatization, can be crosslinked with the aid of a crosslinker, in particular with the aid of the polymer provided according to the invention.
- the Crosslinking can be based in particular on hydrogen bonds, ionic bonds and / or covalent bonds between the albumin and the crosslinker, in particular the polymer provided according to the invention.
- the crosslinking of the albumin is preferably based on the formation of covalent bonds between the albumin and the crosslinker, in particular the polymer provided according to the invention.
- non-terminal monomer units is to be understood as meaning monomer units which are located between terminal, so-called terminal, monomer units of the polymer.
- albumin-crosslinking group or “albumin-crosslinking groups” should or should be understood as meaning groups which crosslink albumin by reaction with functional groups of the albumin, preferably with formation of covalent bonds or Links, effects.
- the term “functionalized” or “functionalizing” is understood to mean any process that is completed, with which the polymer or albumin is given a function, for example by adding groups to the polymer or albumin it does not usually own.
- the non-terminal monomer units are components of a backbone and a backbone of the polymer, respectively.
- non-terminal monomer units are part of a side chain of the polymer.
- terminal monomer units of the polymer further comprise an albumin-crosslinking group.
- the albumin-crosslinking groups of the terminal monomer units may be the same albumin-crosslinking groups as in the case of the non-terminal monomer units.
- all terminal monomer units of the polymer or only a part thereof may have an albumin-crosslinking group.
- terminal monomer units of the polymer are free of an albumin-crosslinking group. In another embodiment, less than 20%, especially less than 10%, preferably less than 5% of the non-terminal monomer units have an albumin-crosslinking group.
- average, i. per polymer molecule, more than two or three, especially more than four, five, six, seven or eight, non-terminal monomer units comprise an albumin-crosslinking group.
- every third monomer unit has up to one thousandth monomer unit, in particular every tenth monomer unit to five hundredth monomer unit, preferably every twentieth monomer unit to one hundredth monomer unit, an albumin-crosslinking group.
- the monomer units mentioned in this paragraph are preferably non-terminal monomer units of the polymer.
- the polymer has a degree of substitution of 33 to 0.1, in particular 10 to 0.2, preferably 5 to 1, thiol groups per 100 monomer units, for example per 100 glucuronic acid units, anhydroglucose units or non-saccharide monomer units.
- 33 to 0.1, in particular from 10 to 0.2, preferably from 5 to 1, per 100 monomer units, for example per 100 glucuronic acid units, anhydroglucose units or non-saccharidic monomer units originally present functional groups, for example OH groups (hydroxy groups) be replaced by thiol groups (SH groups) or thiol-bearing substituents.
- the polymer is a linear, i. unbranched, polymer.
- the polymer is a branched or multi-armed, in particular three- or four-armed, polymer.
- the polymer is a hydrophilic polymer.
- suitable hydrophilic polymers reference is made to the statements made below.
- the polymer is a biocompatible polymer, ie a polymer which is harmless from a medical point of view.
- the polymer has an average molecular weight of 3 kDa to 10,000 kDa, in particular 5 kDa to 1, 000 kDa, preferably 10 kDa to 100 kDa.
- the polymer is a polymer functionalized by the albumin-crosslinking groups.
- the polymer is a polymer selected from the group consisting of albumin-crosslinking functionalized polysaccharide, albumin-crosslinking functionalized mucopolysaccharide, albumin-crosslinking functionalized protein, albumin-crosslinking functionalized groups, synthetic polymer and combinations of at least two of said functionalized polymers.
- the polymer is selected from the group consisting of hyaluronic acid functionalised by albumin-crosslinking groups, carboxymethylcellulose functionalized by albumin-crosslinking groups, dextran functionalized by albumin-crosslinking groups, polyvinyl alcohol functionalized by albumin-crosslinking groups, polyvinylpyrrolidone functionalized by albumin-crosslinking groups and combinations of at least two of said functionalized polymers.
- the polymers mentioned in the previous paragraphs have the particular advantage that they are distinguished by a higher biological compatibility compared to dithio-PEG and at least partly by a faster in vivo degradation or in vivo absorption.
- the combination in particular the second component, is free of polyethylene glycol (PEG) and / or free of a functionalized polyethylene glycol, such as dithio-polyethylene glycol (dithio-PEG).
- PEG polyethylene glycol
- dithio-PEG dithio-polyethylene glycol
- the polymer is an albumin-crosslinking functionalized hyaluronic acid.
- hyaluronic acid as a backbone for the polymer has the advantage that it is a particularly body-affine substance.
- every third disaccharide repeat unit is up to one thousandth disaccharide repeat unit, in particular every tenth disaccharide repeat unit up to five hundredth disaccharide repeat unit, preferably every twentieth disaccharide unit Repeat unit to one hundredth disaccharide repeat unit functionalizing functionalized hyaluronic acid through an albumin-crosslinking group.
- Glucuronic acid units of the hyaluronic acid or of the disaccharide units are particularly preferably functionalized by an albumin-crosslinking group.
- albumin-crosslinking or albumin-reactive groups are each covalently linked via a linker moiety to the carboxy carbon atom of the glucuronic acid units.
- the linker unit preferably has the following formula I.
- the linker unit preferably has the following formula II
- n is an integer from 1 to 12, especially 2 to 4, preferably 2, means.
- the albumin-crosslinking group or the albumin-crosslinking groups are nucleophilic groups or nucleophilic groups, in particular Michael donor group or Michael donor groups, preferably thiol group or thiol groups (US Pat. SH group or SH groups) and / or thiolate or thiolate groups (S " group or S " groups).
- the albumin-crosslinking group or the albumin-crosslinking groups are preferably a thiol group or thiol groups.
- the polymer is a functionalized by thiol groups and / or thiolate groups, ie thiol and / or thiolate functional nalized, hyaluronic acid.
- the polymer is a thiol functionalized hyaluronic acid.
- the polymer has a content of 5 wt.% To 3,000 wt.%, In particular 10 wt.% To 1, 000 wt.%, Preferably 50 wt.% To 200 wt. based on the dry weight of the first component, in particular the crosslinkable albumin and an optional non-functionalized hyaluronic acid contained therein.
- the second component further contains salts, in particular a buffer such as dihydrogen phosphate-hydrogen phosphate buffer and / or bicarbonate bicarbonate buffer.
- the second component is in the form of an aqueous liquid, in particular in the form of an aqueous suspension or aqueous solution, preferably in the form of an aqueous solution.
- the crosslinkable albumin in another embodiment, is crosslinkable serum albumin, i. a crosslinkable albumin derived from blood serum.
- the crosslinkable albumin may be a synthetic, i. is an albumin produced in a chemical laboratory or similar facility, or a recombinantly produced albumin.
- albumin may be human or xenogenic, especially porcine, bovine or equine.
- crosslinkable albumin is an albumin of human origin.
- the crosslinkable albumin is a functionalized albumin, in particular an albumin functionalized by electrophilic groups, in particular Michael acceptor groups, preferably thiol-reactive groups.
- thiol-reactive groups is to be understood as meaning functional groups which are capable of reacting with thiol groups, preferably with the formation of covalent bonds or linkages.
- the groups mentioned in the previous paragraph are selected from the group consisting of maleimide groups, vinylsulfone groups, acrylate groups, alkyl halide groups, azirole groups, pyridyl groups, thionitrobenzenic acid groups, arylating groups, and combinations of at least two of said functional groups.
- the albumin is preferably functionalized by groups selected from the group consisting of maleimide groups, vinylsulfone groups, acrylate groups, alkyl halide groups, azirole groups, pyridyl groups, thionitrobenzenic acid groups, arylating groups and combinations of at least two of said functional groups.
- the crosslinkable albumin is a maleimide group functionalized, i. maleimide functionalized albumin, preferably a maleimide group functionalized, i. maleimide-functionalized, serum albumin.
- the combination is a biocompatible, especially medically effective, preferably therapeutically effective, combination.
- the combination in particular the first component and / or the second component, preferably the first component, in a further embodiment further comprises cells, in particular mammalian cells, preferably selected from the group consisting of musculoskeletal cells, metabolic regulating gland cells, islet cells, melatonin-producing Cells, progenitor cells, stem cells, in particular mesenchymal stem cells, and combinations of at least two of said cell types.
- cells in particular mammalian cells, preferably selected from the group consisting of musculoskeletal cells, metabolic regulating gland cells, islet cells, melatonin-producing Cells, progenitor cells, stem cells, in particular mesenchymal stem cells, and combinations of at least two of said cell types.
- the musculoskeletal cells are preferably stem cells, chondrocytes, osteocytes, fibrochondrocytes or a combination of at least two of the mentioned cell types.
- the autologous cells are preferably autologous chondrocytes, autologous disc chondrocytes, autologous stem cells, autologous mesenchymal stem cells or a combination of at least two of the mentioned cell types.
- the combination in particular the first component and / or the second component, preferably the first component, at least one active ingredient, in particular pharmaceutical or biological active ingredient.
- the active ingredient is preferably selected from the group consisting of antibiotic, antiinflammatory, metabolic hormone, chondroprotective agent such as hyaluronic acid, bone morphogenetic protein such as BMP-2, gene therapy agent, growth hormone, differentiation or modulation factor, immunosuppressant, immunostimulating substance , DNA, RNA, nucleic acid, apoptosis-inducing agent, adhesion-promoting agent, receptor antagonist and combinations of at least two of said active substances.
- the combination in particular the first component and / or the second component, preferably contains the first component, hyaluronic acid, i. unfunctionalized hyaluronic acid.
- the combination in particular the first component and / or the second component, preferably the first component, preferably contains from 0.1% by weight to 5% by weight, in particular from 0.2% by weight to 3% by weight, of hyaluronic acid. , preferably 0.5 wt .-% to 2 wt .-%, based on the total weight of the two components dissolved in water.
- the combination in particular the first component and / or the second component, preferably the first component, is free of hyaluronic acid.
- the first component is in the form of an aqueous liquid, in particular in the form of an aqueous solution or aqueous suspension, preferably in the form of an aqueous suspension.
- the first component is in the form of an aqueous cell suspension, i. in the form of an aqueous suspension containing cells.
- the combination is in the form of a medical product or medical product, preferably in the form of an implant.
- the combination may be in the form of a cell-free implant.
- the combination is in the form of a drug for advanced therapies, in particular in the form of a cell or inoculated implant or tissue engineering product (biotechnologically processed tissue preparation).
- the combination is a combination for use in the prophylaxis of pathological tissue adhesions, in particular tissue growths in the abdomen or in other areas.
- the combination is a combination for use in the treatment, in particular reconstruction, of a cartilage defect, in particular a joint cartilage defect, preferably knee cartilage defect, or disc defect, preferably lumbar disc defect, more preferably lumbar-sacral disc defect.
- the combination is a combination for use in the treatment, in particular reconstruction, of a defect of the annulus fibrosus and / or nucleus pulposus, preferably of the nucleus pulposus.
- the combination is prepared for a surgical, in particular minimally invasive, administration.
- the combination according to another embodiment is used for a surgical, in particular minimally invasive, administration.
- the combination is prepared for facet joint infiltration, in particular for peri- and / or intra-articular facet joint infiltration, preferably intra-articular facet joint infiltration.
- the combination is used for facet joint infiltration, in particular peri- and / or intra-articular facet joint infiltration, preferably intra-articular facet joint infiltration.
- the combination is in the form of a kit, in particular in the form of a medical, preferably surgical, kit.
- the invention relates in a second aspect to a reaction product.
- the reaction product is obtained by mixing a first component containing crosslinkable albumin and a second component containing a polymer, wherein non-terminal monomer units of the polymer at least partially, in particular only partially, have an albumin-crosslinking group, in particular by mixing a first component and a second component of a combination according to the first aspect of the invention, obtainable or producible.
- the formation of the reaction product is due to a cross-linking reaction occurring between the crosslinkable albumin and the polymer which cross-links albumin molecules via macromolecules of the polymer, preferably to form a hydrogel.
- reaction product prefferably be a hydrogel.
- the invention relates to a medical device.
- the medical device has spatially separated from each other a first component containing crosslinkable albumin, and a second component containing a polymer, wherein non-terminal monomer units of the polymer at least partially, in particular only partially, an albumin-crosslinking group, in particular a combination according to first aspect of the invention.
- the medical device is preferably an implant, in particular a cell-free implant.
- the invention relates to a drug for advanced therapies.
- the advanced therapy medicinal product comprises, spatially separated from each other, a first component containing crosslinkable albumin, and a second component containing a polymer, wherein non-terminal monomeric units of the polymer are at least partially, in particular special only partially, have an albumin-crosslinking group, in particular a combination according to the first aspect of the invention on.
- the advanced therapy medicinal product is preferably an inoculated or inoculated implant or a tissue engineering product (biotechnologically processed tissue preparation).
- the invention relates to a kit.
- the kit comprises, spatially separated from one another, a first component containing crosslinkable albumin, and a second component containing a polymer, wherein non-terminal monomer units of the polymer at least partially, in particular only partially, have an albumin-crosslinking group, in particular a combination according to the first aspect of the invention ,
- the invention relates to a discharge device.
- the discharge device has spatially separated from each other a first component containing crosslinkable albumin, and a second component containing a polymer, wherein non-terminal monomer units of the polymer at least partially, in particular only partially, have an albumin-crosslinking group, in particular a combination according to first aspect of the invention.
- the discharge device is preferably a multi-chamber discharge device, in particular a two-chamber discharge device.
- the discharge device can be designed as a twin syringe.
- the invention relates to a method for producing a combination, in particular a combination according to the first aspect of the invention.
- the method comprises the following steps:
- the invention relates to a process for the preparation of a reaction product, preferably hydrogel, in particular according to the second aspect of the invention.
- the method comprises the following steps: a) providing a first component which contains crosslinkable albumin, b) optionally adding cells, in particular autologous cells and / or active substances, c) adding a crosslinking polymer, wherein non-terminal monomer units of the polymer at least partially, in particular only partially, have an albumin-crosslinking group.
- the invention relates to the use of a polymer for cross-linking crosslinkable albumin, wherein non-terminal monomer units of the polymer at least partially, in particular only partially, have an albumin-crosslinking group.
- the invention relates to a functionalized hyaluronic acid.
- the functionalized hyaluronic acid is characterized in particular by the fact that every third disaccharide repeating unit contains up to one thousandth disaccharide repeating unit, in particular every tenth disaccharide repeating unit to five hundredth disaccharide repeating unit, preferably every twentieth disaccharide repeating unit to one hundredth disaccharide repeating unit, of the functionalized hyaluronic acid Albumin-crosslinking group is functionalized.
- Glucuronic acid units of the hyaluronic acid or of the disaccharide units are particularly preferably functionalized by an albumin-crosslinking group.
- the albumin-reactive groups are each covalently linked via a linker moiety to the carboxy carbon atom of the glucuronic acid units.
- the linker unit preferably has the following formula I.
- n is an integer from 1 to 12, in particular 2 to 4, preferably 2.
- the linker unit preferably has the following formula II
- n is an integer from 1 to 12, in particular 2 to 4, preferably 2, means.
- the albumin-crosslinking group or the albumin-crosslinking groups are nucleophilic groups or nucleophilic groups, in particular Michael donor group or Michael donor groups, preferably thiol group or thiol groups (US Pat. SH group or SH groups) and / or thiolate group or thiolate groups (S " group or S groups) .
- the albumin-crosslinking group or the albumin-crosslinking groups is preferably a thiol group or to thiol groups.
- a low-loaded thiol-functionalized hyaluronic acid was synthesized.
- hyaluronic acid (average molecular weight 57 kDa) was activated with 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide (EDC) at pH 4.75 and then with an excess of shot of 3,3'-dithiobis (propanoic dihydrazide) modified. After removal of excess 3,3'-dithiobis (propanoic dihydrazide) by dialysis, the disulfide of the hydrazide coupled to the hyaluronic acid was reduced with tris (2-carboxyethyl) phosphine.
- EDC 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide
- the thiol-functionalized hyaluronic acid prepared according to Example 1 was added to the maleimide-functionalized albumin prepared according to Example 2. Within a few minutes, a hydrogel was obtained which showed no separation tendency.
- carboxymethylcellulose (average molecular weight 90 kDa, degree of functionalization 0.75, ie 0.75 carboxyl groups per anhydroglucose unit) was dissolved in water and dissolved in various mixtures of 0.30, 0.15 and 0.075 molar equivalents (on Carboxy groups) 4- (4,6-dimethoxy-1,3,5-triazin-2-yl) -4-methylmorpholinium chloride (DMTMM, CAS 3945-69-5) and then with an excess of cystamine dihydrochloride at pH 6 , 5-7 implemented.
- DTMM 4,6-dimethoxy-1,3,5-triazin-2-yl
- the thiol-functionalized carboxymethylcellulose prepared according to Example 4 with a degree of substitution of 3.6 was added to a maleimide-functionalized albumin prepared according to Example 2 and also PBS.
- the reactive groups (thiol or maleimide groups) were each calculated to a concentration of 2 mmol / L in the mixture. Within a few minutes, a hydrogel was obtained which showed no separation tendency.
- hydrogel could be prepared in the same way with the thiol-functionalized carboxymethylcellulose prepared according to Example 4 with a degree of substitution of 2.1, which showed no tendency to separate.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Developmental Biology & Embryology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Botany (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Physiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dispersion Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102016216182.2A DE102016216182A1 (de) | 2016-08-29 | 2016-08-29 | Kombination, insbesondere zum Behandeln eines Knorpeldefekts |
PCT/EP2017/071560 WO2018041784A1 (de) | 2016-08-29 | 2017-08-28 | Kombination mit albumin, insbesondere zum behandeln eines knorpeldefekts |
Publications (1)
Publication Number | Publication Date |
---|---|
EP3504232A1 true EP3504232A1 (de) | 2019-07-03 |
Family
ID=59829341
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP17764530.6A Pending EP3504232A1 (de) | 2016-08-29 | 2017-08-28 | Kombination mit albumin, insbesondere zum behandeln eines knorpeldefekts |
Country Status (7)
Country | Link |
---|---|
US (1) | US11065364B2 (de) |
EP (1) | EP3504232A1 (de) |
JP (1) | JP7245152B2 (de) |
CN (1) | CN109890840A (de) |
CA (1) | CA3035288A1 (de) |
DE (1) | DE102016216182A1 (de) |
WO (1) | WO2018041784A1 (de) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102017207049A1 (de) * | 2017-04-26 | 2018-10-31 | Tetec Tissue Engineering Technologies Ag | Zellfreie Kombination, hydrogelartiges Material oder Hydrogel sowie Verwendungen davon |
EP4215179A1 (de) | 2022-01-21 | 2023-07-26 | Freie Universität Berlin | Hydrogel mit dendritischen polyglycerineinheiten und polyethereinheiten |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1302534B1 (it) * | 1998-12-21 | 2000-09-05 | Fidia Advanced Biopolymers Srl | Composizioni iniettabili, biocompatibili e biodegradabili comprendentialmeno un derivato dell'acido ialuronico, cellule condrogeniche, per |
DE102008008071A1 (de) | 2008-01-28 | 2009-08-06 | NMI Naturwissenschaftliches und Medizinisches Institut an der Universität Tübingen | Injizierbare biokompatible Zusammensetzung |
US8968785B2 (en) * | 2009-10-02 | 2015-03-03 | Covidien Lp | Surgical compositions |
DE102009051575A1 (de) * | 2009-10-26 | 2011-04-28 | NMI Naturwissenschaftliches und Medizinisches Institut an der Universität Tübingen | Verwendung von biokompatiblen Zusammensetzungen und hieraus polymerisierten Materialien zur Inhibierung der Angiogenese |
DE102010009876A1 (de) | 2010-02-23 | 2011-09-08 | Cellendes Gmbh | Vernetzer für Hydrogele |
MX349070B (es) * | 2010-11-23 | 2017-07-07 | Elastagen Pty Ltd | Preparacion y/o formulacion de proteinas reticuladas con polisacaridos. |
WO2014153541A1 (en) * | 2013-03-21 | 2014-09-25 | Eupraxia Pharmaceuticals USA LLC | Injectable sustained release composition and method of using the same for treating inflammation in joints and pain associated therewith |
-
2016
- 2016-08-29 DE DE102016216182.2A patent/DE102016216182A1/de not_active Withdrawn
-
2017
- 2017-08-28 EP EP17764530.6A patent/EP3504232A1/de active Pending
- 2017-08-28 WO PCT/EP2017/071560 patent/WO2018041784A1/de active Application Filing
- 2017-08-28 CN CN201780066900.8A patent/CN109890840A/zh active Pending
- 2017-08-28 CA CA3035288A patent/CA3035288A1/en not_active Abandoned
- 2017-08-28 JP JP2019511747A patent/JP7245152B2/ja active Active
- 2017-08-28 US US16/329,647 patent/US11065364B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US20190192733A1 (en) | 2019-06-27 |
DE102016216182A1 (de) | 2018-03-01 |
WO2018041784A1 (de) | 2018-03-08 |
CA3035288A1 (en) | 2018-03-08 |
US11065364B2 (en) | 2021-07-20 |
JP7245152B2 (ja) | 2023-03-23 |
JP2019528837A (ja) | 2019-10-17 |
CN109890840A (zh) | 2019-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60316291T2 (de) | Esterderivate von hyaluronsäure zur herstellung von hydrogelmaterialien durch photohärtung | |
DE69922522T2 (de) | Funktionalisierte hyaluronsäurederivate, bildung von hydrogelen und deren verwendung in situ | |
DE60104703T2 (de) | Neue vernetzte derivate der hyaluronsäure. | |
DE69903351T3 (de) | Vernetzte hyaluronsäure und ihre medizinischen verwendungen | |
DE602005005062T2 (de) | Hyaluronsäure und alpha-, beta-polyaspartylhydrazidhydrogele und deren biomedizinischen und pharmazeutischen anwendungen | |
DE60014400T2 (de) | Antiadhäsionsschicht aus hyaluronsäure | |
ES2811101T3 (es) | Procedimiento para la preparación y purificación de la sal de sodio de ácido hialurónico | |
EP1126881B1 (de) | Mucoadhäsive polymere, deren verwendung sowie deren herstellungsverfahren | |
DE60123225T2 (de) | Clathratekomplexe auf der basis von hyaluronsäurederivaten und deren verwendung als arzneimittel | |
CN117582559A (zh) | 用于治疗医疗植入物部位的方法和系统 | |
MXPA06007556A (es) | Geles cohesivos de hialuronano y/o hilano entrecruzados, su preparacion y su uso. | |
CA2810590A1 (en) | Mercapto-modified biocompatible macromolecule derivatives with low degree of mercapto-modification and the cross-linked materials and uses thereof | |
BR112013012772B1 (pt) | Preparação e/ou formulação de proteínas reticuladas com polissacarídeos | |
US20210236692A1 (en) | Regeneration of diseases intervertebral discs | |
WO2020262642A1 (ja) | 化学架橋アルギン酸を用いた移植用デバイス | |
DE102012104530A1 (de) | Verwendung einer biokompatiblen Zusammensetzung | |
WO2018041784A1 (de) | Kombination mit albumin, insbesondere zum behandeln eines knorpeldefekts | |
US20230301906A1 (en) | Biocompatible, injectable and in situ gelling hydrogels and preparation and applications of biocompatible, injectable and in situ gelling hydrogels based on cellulose nanofibrils for tissue and organ repair | |
CN110431154B (zh) | 用天然或半合成交联剂交联的透明质酸 | |
EP2717885B1 (de) | Antiinfektives mittel | |
CN112516075A (zh) | 一种载有泼尼松的透明质酸-壳聚糖温敏水凝胶及其制备方法 | |
DE60004011T2 (de) | Zusammensetzung von fluorinierten polymeren zur vermeidung chirurgischer verklebungen und gewebeschäden | |
CN111732675A (zh) | 透明质酸-氨基葡萄糖接枝共聚物、制法及其应用 | |
DE212020000715U1 (de) | Hydrogel auf der Basis eines vernetzten Hydroxyphenylderivats der Hyaluronsäure | |
DE60110421T2 (de) | Implantierbare zusammensetzungen enthaltend niedermoleculare zellulosederivate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20190311 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20200608 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |